Neuroinflammation, immune response and α-synuclein pathology: how animal models are helping us to connect dots

References

• Masgrau R, Guaza C, Ransohoff RM, et al. Should we stop saying ‘glia’ and ‘neuroinflammation’? Trends Mol Med. 2017;23(6):486–500.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Tago H, et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79(1–2):195–200.
   PubMed Web of Science ®Google Scholar
• Rogers J, Luber-Narod J, Styren SD, et al. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol Aging. 1988;9:339–349.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 1988;76(6):550–557.
   PubMed Web of Science ®Google Scholar
• Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci. 2002;14(2):223–236.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8):1285–1291.
   PubMed Web of Science ®Google Scholar
• Kouli A, Camacho M, Allinson K, et al. Neuroinflammation and protein pathology in Parkinson’s disease dementia. Acta Neuropathol Commun. 2020;8(1):211.
   PubMed Web of Science ®Google Scholar
• Lavisse S, Goutal S, Wimberley C, et al. Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. Parkinsonism Relat Disord. 2021;82:29–36.
   PubMed Web of Science ®Google Scholar
• Wijeyekoon RS, Moore SF, Farrell K, et al. Cerebrospinal fluid cytokines and neurodegeneration-associated proteins in Parkinson’s Disease. Mov Disord. 2020;35(6):1062–1066.
   PubMed Web of Science ®Google Scholar
• Blesa J, Foffani G, Dehay B, et al. Motor and non-motor circuit disturbances in early Parkinson disease: which happens first? Nat Rev Neurosci. 2022;23(2):115–128.
   PubMed Web of Science ®Google Scholar
• Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol. 2020;19(2):170–178.
   PubMed Web of Science ®Google Scholar
• Klein C, Westenberger A. Genetics of Parkinson’s Disease. Cold Spring Harb Perspect Med. 2012;2(1):a008888–a008888.
   PubMed Web of Science ®Google Scholar
• Blesa J, Przedborski S. Parkinson’s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat. 2014;8:155.
   PubMed Web of Science ®Google Scholar
• Terkelsen MH, Klaestrup IH, Hvingelby V, et al. Neuroinflammation and immune changes in prodromal Parkinson’s Disease and Other Synucleinopathies. J Parkinsons Dis. 2022;12(s1):S149–S163.
   PubMedGoogle Scholar
• Stokholm MG, Iranzo A, Østergaard K, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 2017;16(10):789–796.
   PubMed Web of Science ®Google Scholar
• Stokholm MG, Iranzo A, Østergaard K, et al. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiol Dis. 2018;115:9–16.
   PubMed Web of Science ®Google Scholar
• Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21(2):404–412.
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. 2005;57(2):168–175.
   PubMed Web of Science ®Google Scholar
• Lindestam Arlehamn CS, Dhanwani R, Pham J, et al. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nat Commun. 2020;11(1):1875.
   PubMed Web of Science ®Google Scholar
• Farmen K, Nissen SK, Stokholm MG, et al. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proc Natl Acad Sci U S A. 2021;118(10):e2020858118.
   PubMed Web of Science ®Google Scholar
• Konstantin Nissen S, Farmen K, Carstensen M, et al. Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson’s disease and cognition. Brain Behav Immun. 2022;101:182–193.
   PubMed Web of Science ®Google Scholar
• Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson’s disease: glia in Parkinson’s Disease. Mov Disord. 2011;26(1):6–17.
   PubMed Web of Science ®Google Scholar
• Tansey MG, Wallings RL, Houser MC, et al. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22:657–673.
   PubMed Web of Science ®Google Scholar
• Del Rey NL-G, Quiroga-Varela A, Garbayo E, et al. Advances in Parkinson’s Disease: 200 years later. Front Neuroanat. 2018;12:113.
   PubMed Web of Science ®Google Scholar
• Bourdenx M, Martín-Segura A, Scrivo A, et al. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell. 2021;184(10):2696–2714.e25.
   PubMed Web of Science ®Google Scholar
• Imamura K, Hishikawa N, Sawada M, et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol. 2003;106(6):518–526.
   PubMed Web of Science ®Google Scholar
• Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol. 2019;18(6):573–586.
   PubMed Web of Science ®Google Scholar
• Koprich JB, Kalia LV, Brotchie JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci. 2017;18(9):515–529.
   PubMed Web of Science ®Google Scholar
• Gao H-M, Zhang F, Zhou H, et al. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect. 2011;119(6):807–814.
   PubMed Web of Science ®Google Scholar
• Kim S, Kwon S-H, Kam T-I, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s Disease. Neuron. 2019;103(4):627–641.e7.
   PubMed Web of Science ®Google Scholar
• Wang S, Chu C-H, Stewart T, et al. α-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation. Proc Natl Acad Sci U S A. 2015;112:E1926–1935.
   PubMed Web of Science ®Google Scholar
• Blesa J, Trigo-Damas I, Quiroga-Varela A, et al. Oxidative stress and Parkinson’s disease. Front Neuroanat. 2015;9:91.
   PubMed Web of Science ®Google Scholar
• Li W, Fu Y, Halliday GM, et al. PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic parkinson’s disease. Front Cell Dev Biol. 2021;9:612476.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM-Y, et al. α-Synuclein in Lewy bodies. Nature. 1997;388(6645):839–840.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–2047.
   PubMed Web of Science ®Google Scholar
• Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998;18(2):106–108.
   PubMed Web of Science ®Google Scholar
• Javed H, Menon SA, Al-Mansoori KM, et al. Development of nonviral vectors targeting the brain as a therapeutic approach for parkinson’s disease and other brain disorders. Mol Ther. 2016;24(4):746–758.
   PubMed Web of Science ®Google Scholar
• Su X, Maguire-Zeiss KA, Giuliano R, et al. Synuclein activates microglia in a model of Parkinson’s Disease. Neurobiol Aging. 2008;29(11):1690–1701.
   PubMed Web of Science ®Google Scholar
• Watson MB, Richter F, Lee SK, et al. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol. 2012;237(2):318–334.
   PubMed Web of Science ®Google Scholar
• X-l G, Long C-X, Sun L, et al. Astrocytic expression of Parkinson’s disease-related A53T α-synuclein causes neurodegeneration in mice. Mol Brain. 2010;3(1):12.
   PubMedGoogle Scholar
• Miller RM, Kiser GL, Kaysser-Kranich T, et al. Wild-type and mutant α-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Exp Neurol. 2007;204(1):421–432.
   PubMed Web of Science ®Google Scholar
• Iba M, Kim C, Sallin M, et al. Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models. J Neuroinflammation. 2020;17(1):214.
   PubMed Web of Science ®Google Scholar
• Tan E-K, Chao Y-X, West A, et al. Parkinson disease and the immune system — associations, mechanisms and therapeutics. Nat Rev Neurol. 2020;16(6):303–318.
   PubMed Web of Science ®Google Scholar
• Deverman BE, Pravdo PL, Simpson BP, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016;34(2):204–209.
   PubMed Web of Science ®Google Scholar
• Volpicelli-Daley LA, Kirik D, Stoyka LE, et al. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson’s disease? J Neurochem. 2016;139 Suppl 1:131–155.
   PubMed Web of Science ®Google Scholar
• Theodore S, Cao S, McLean PJ, et al. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol. 2008;67(12):1149–1158.
   PubMed Web of Science ®Google Scholar
• Chung CY, Koprich JB, Siddiqi H, et al. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci. 2009;29(11):3365–3373.
   PubMed Web of Science ®Google Scholar
• Cao S, Theodore S, Standaert DG. Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson’s disease. Mol Neurodegener. 2010;5(1):42.
   PubMedGoogle Scholar
• Choi I, Zhang Y, Seegobin SP, et al. Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration. Nat Commun. 2020;11(1):1386.
   PubMed Web of Science ®Google Scholar
• H-y T, Yuan B-S, Hou X-O, et al. α-synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson’s disease. Aging Cell. 2021;20(12):e13522.
   PubMed Web of Science ®Google Scholar
• Thome AD, Standaert DG, Harms AS. Fractalkine signaling regulates the inflammatory response in an α-synuclein model of Parkinson Disease. PLoS One. 2015;10(10):e0140566.
   PubMed Web of Science ®Google Scholar
• Van der Perren A, Macchi F, Toelen J, et al. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson’s disease. Neurobiol Aging. 2015;36(3):1559–1568.
   PubMed Web of Science ®Google Scholar
• Harms AS, Thome AD, Yan Z, et al. Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Exp Neurol. 2018;300:179–187.
   PubMed Web of Science ®Google Scholar
• Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in non-transgenic mice. Science. 2012;338(6109):949–953.
   PubMed Web of Science ®Google Scholar
• Volpicelli-Daley LA, Luk KC, Lee VM-Y. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite–like aggregates. Nat Protoc. 2014;9(9):2135–2146.
   PubMed Web of Science ®Google Scholar
• Polinski NK, Volpicelli-Daley LA, Sortwell CE, et al. Best practices for generating and using alpha-synuclein pre-formed fibrils to model parkinson’s disease in rodents. JPD. 2018;8(2):303–322.
   Google Scholar
• Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72(1):57–71.
   PubMed Web of Science ®Google Scholar
• Sznejder-Pachołek A, Joniec-Maciejak I, Wawer A, et al. The effect of α-synuclein on gliosis and IL-1α, TNFα, IFNγ, TGFβ expression in murine brain. Pharmacol Rep. 2017;69(2):242–251.
   PubMed Web of Science ®Google Scholar
• Harms AS, Delic V, Thome AD, et al. α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol Commun. 2017;5(1):85.
   PubMedGoogle Scholar
• Izco M, Blesa J, Verona G, et al. Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson’s disease. Neurosci Res. 2021;170:330–340.
   PubMed Web of Science ®Google Scholar
• Stoll AC, Sortwell CE. Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity. Neurobiol Dis. 2022;171:105804.
   PubMed Web of Science ®Google Scholar
• Duffy MF, Collier TJ, Patterson JR, et al. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation. 2018;15(1):129.
   PubMedGoogle Scholar
• Garcia P, Jürgens-Wemheuer W, Uriarte Huarte O, et al. Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson’s disease. Glia. 2022;70(5):935–960.
   PubMed Web of Science ®Google Scholar
• Hinkle JT, Patel J, Panicker N, et al. STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy. Proc Natl Acad Sci U S A. 2022;119(15):e2118819119.
   PubMed Web of Science ®Google Scholar
• Guo M, Wang J, Zhao Y, et al. Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease. Brain. 2020;143(5):1476–1497.
   PubMed Web of Science ®Google Scholar
• La Vitola P, Balducci C, Cerovic M, et al. Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain Behav Immun. 2018;69:591–602.
   PubMed Web of Science ®Google Scholar
• Kim C, Ho D-H, Suk J-E, et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4(1):1562.
   PubMedGoogle Scholar
• Yang Y, Song -J-J, Choi YR, et al. Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson’s disease. Proc Natl Acad Sci U S A. 2022;119(29):e2110746119.
   PubMed Web of Science ®Google Scholar
• Trigo-Damas I, Del Rey NL-G, Blesa J. Novel models for Parkinson’s disease and their impact on future drug discovery. Expert Opin Drug Discov. 2018;13(3):229–239.
   PubMed Web of Science ®Google Scholar
• Gispert S, Del Turco D, Garrett L, et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci. 2003;24(2):419–429.
   PubMed Web of Science ®Google Scholar
• Yavich L, Oksman M, Tanila H, et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human α-synuclein. Neurobiol Dis. 2005;20(2):303–313.
   PubMed Web of Science ®Google Scholar
• Hallett PJ, McLean JR, Kartunen A, et al. Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis. 2012;47(2):258–267.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Suk J-E, Lee K-W, et al. Transmission of synucleinopathies in the enteric nervous system of A53T alpha-synuclein transgenic mice. Exp Neurobiol. 2011;20(4):181–188.
   PubMedGoogle Scholar
• Emmer KL, Waxman EA, Covy JP, et al. E46K human α-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem. 2011;286:35104–35118.
   PubMed Web of Science ®Google Scholar
• Rockenstein E, Mallory M, Hashimoto M, et al. Differential neuropathological alterations in transgenic mice expressing ?-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002;68(5):568–578.
   PubMed Web of Science ®Google Scholar
• Huntington TE, Srinivasan R. Adeno-associated virus expression of α-synuclein as a tool to model parkinson’s disease: current understanding and knowledge gaps. Aging Dis. 2021;12(4):1120.
   PubMed Web of Science ®Google Scholar
• Osterberg VR, Spinelli KJ, Weston LJ, et al. Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 2015;10(8):1252–1260.
   PubMed Web of Science ®Google Scholar
• Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med. 2012;209(5):975–986.
   PubMed Web of Science ®Google Scholar
• Choi YR, Kim J-B, Kang S-J, et al. The dual role of c-src in cell-to-cell transmission of α-synuclein. EMBO Rep. 2020;21(7):e48950.
   PubMed Web of Science ®Google Scholar
• Sacino AN, Brooks M, Thomas MA, et al. Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 2014;127(5):645–665.
   PubMed Web of Science ®Google Scholar
• Schaser AJ, Stackhouse TL, Weston LJ, et al. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy. Acta Neuropathol Commun. 2020;8(1):150.
   PubMed Web of Science ®Google Scholar
• Lohmann S, Bernis ME, Tachu BJ, et al. Oral and intravenous transmission of α-synuclein fibrils to mice. Acta Neuropathol. 2019;138(4):515–533.
   PubMed Web of Science ®Google Scholar
• Björklund A, Nilsson F, Mattsson B, et al. A Combined α-synuclein/fibril (SynFib) model of Parkinson-like synucleinopathy targeting the nigrostriatal dopamine system. J Parkinsons Dis. 2022;12(8):2307–2320.
   PubMedGoogle Scholar
• Pacheco R. T-cell based immunotherapies for Parkinson's disease. Explor Neuroprot Ther. 2021;1(2):72–85
   Google Scholar
• Williams GP, Schonhoff AM, Jurkuvenaite A, et al. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson’s disease. Brain. 2021;144(7):2047–2059.
   PubMedGoogle Scholar
• Mosley RL, Lu Y, Olson KE, et al. A synthetic agonist to vasoactive intestinal peptide receptor-2 induces regulatory T cell neuroprotective activities in models of Parkinson’s Disease. Front Cell Neurosci. 2019;13:421.
   PubMed Web of Science ®Google Scholar
• Olson KE, Namminga KL, Lu Y, et al. Granulocyte-macrophage colony-stimulating factor mRNA and neuroprotective immunity in Parkinson’s disease. Biomaterials. 2021;272:120786.
   PubMed Web of Science ®Google Scholar
• Rockenstein E, Ostroff G, Dikengil F, et al. Combined active humoral and cellular immunization approaches for the treatment of synucleinopathies. J Neurosci. 2018;38(4):1000–1014.
   PubMed Web of Science ®Google Scholar
• Villadiego J, Labrador-Garrido A, Franco JM, et al. Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model. Glia. 2018;66(1):191–205.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ma H, Wang X, et al. Protective effect of the α7 nicotinic receptor agonist PNU-282987 on dopaminergic neurons against 6-hydroxydopamine, regulating anti-neuroinflammatory and the immune balance pathways in rat. Front Aging Neurosci. 2020;12:606927.
   PubMed Web of Science ®Google Scholar
• Motyl J, Przykaza Ł, Boguszewski PM, et al. Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson’s disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology. 2018;135:139–150.
   PubMed Web of Science ®Google Scholar
• Zhao P, Yang X, Yang L, et al. Neuroprotective effects of fingolimod in mouse models of Parkinson’s disease. FASEB J. 2017;31(1):172–179.
   PubMed Web of Science ®Google Scholar
• Bido S, Muggeo S, Massimino L, et al. Microglia-specific overexpression of α-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. Nat Commun. 2021;12(1):6237.
   PubMed Web of Science ®Google Scholar
• Pediaditakis I, Kodella KR, Manatakis DV, et al. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nat Commun. 2021;12(1):5907.
   PubMed Web of Science ®Google Scholar
• Charvin D, Medori R, Hauser RA, et al. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018;17(11):804–822.
   PubMed Web of Science ®Google Scholar
• Bezard E. How lazy reading and semantic sloppiness may harm progress in synucleinopathy research. Biomolecules. 2022;12(2):228.
   PubMed Web of Science ®Google Scholar
• McFarthing K, Rafaloff G, Baptista M, et al. Parkinson’s disease drug therapies in the clinical trial pipeline: 2022 update. J Parkinsons Dis. 2022;12(4):1073–1082.
   PubMedGoogle Scholar
• Reading CL, Ahlem CN, Murphy MF. NM101 Phase III study of NE3107 in Alzheimer’s disease: rationale, design  and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag. 2021;11(4):289–298.
   PubMedGoogle Scholar
• Khan RS, Dine K, Luna E, et al. HE3286 reduces axonal loss and preserves retinal ganglion cell function in experimental optic neuritis. Invest Ophthalmol Vis Sci. 2014;55(9):5744–5751.
   PubMed Web of Science ®Google Scholar
• Lambert WS, Carlson BJ, Formichella CR, et al. Oral delivery of a synthetic sterol reduces axonopathy and inflammation in a rodent model of glaucoma. Front Neurosci. 2017;11:45.
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Philippens I, Fagone P, et al. 17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) is neuroprotective and reduces motor impairment and neuroinflammation in a murine MPTP model of Parkinson’s Disease. Parkinson's Dis. 2012;2012:969418.
   PubMed Web of Science ®Google Scholar
• Reynolds AD, Banerjee R, Liu J, et al. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol. 2007;82(5):1083–1094.
   PubMed Web of Science ®Google Scholar
• Gendelman HE, Zhang Y, Santamaria P, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. NPJ Parkinson's Dis. 2017;3(1):10.
   PubMedGoogle Scholar
• Olson KE, Namminga KL, Lu Y, et al. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson’s disease. E Bio Medicine. 2021;67:103380.
   Google Scholar
• Sun D, Gao W, Hu H, et al. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049–3062.
   PubMed Web of Science ®Google Scholar
• Seyhan AA. Lost in translation: the Valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. Transl Med Commun. 2019;4(1):18
   Google Scholar
• Klæstrup IH, Just MK, Holm KL, et al. Impact of aging on animal models of Parkinson’s disease. Front Aging Neurosci. 2022;14:909273.
   PubMedGoogle Scholar
• Del Rey NL-G, Balzano T, Martin-Rodriguez L, et al. Lack of Parkinsonian pathology and neurodegeneration in mice after long-term injections of a proteasome inhibitor in olfactory bulb and amygdala. Front Aging Neurosci. 2021;13:698979.
   PubMed Web of Science ®Google Scholar
• Martínez-Cué C, Rueda N. Cellular senescence in neurodegenerative diseases. Front Cell Neurosci. 2020;14:16.
   PubMed Web of Science ®Google Scholar
• Coleman C, Martin I. Unraveling Parkinson’s disease neurodegeneration: does aging hold the clues? J Parkinson's Dis. 2022;12(8):2321–2338.
   PubMedGoogle Scholar
• Takami Y, Wang C, Nakagami H, et al. Novel pathophysiological roles of α-synuclein in age-related vascular endothelial dysfunction. FASEB J. 2022;36(10):e22555.
   PubMed Web of Science ®Google Scholar
• T-y H, Choi YR, Noh HR, et al. Age-related increase in caveolin-1 expression facilitates cell-to-cell transmission of α-synuclein in neurons. Mol Brain. 2021;14(1):122.
   PubMed Web of Science ®Google Scholar
• Iba M, McDevitt RA, Kim C, et al. Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in  a mouse model of DLB/PD. Mol Neurodegener. 2022;17(1):60.
   PubMed Web of Science ®Google Scholar
• Rauschenberger L, Behnke J, Grotemeyer A, et al. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson’s disease. Neurobiol Dis. 2022;171:105798.
   PubMed Web of Science ®Google Scholar
• Galet B, Cheval H, Ravassard P. Patient-derived midbrain organoids to explore the molecular basis of Parkinson’s disease. Front Neurol. 2020;11:1005.
   PubMed Web of Science ®Google Scholar
• Olson KE, Gendelman HE. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson’s disease. Curr Opin Pharmacol. 2016;26:87–95.
   PubMed Web of Science ®Google Scholar